7 rezultatet
FIELD OF THE INVENTION
This invention relates to methods for diagnosing a person's susceptibility for having an increased risk for the development of atherosclerosis and a diabetic person's susceptibility for having an increased risk for the development of diabetic retinopathy. The invention relates
PRIORITY TO RELATED APPLICATIONS
This application claims the benefit of European Patent Application No. 11188728.7, filed Nov. 11, 2011, which is hereby incorporated by reference in its entirety.
SUMMARY OF THE INVENTION
The invention relates to a process for the preparation of a proline derivative
The present invention relates to certain substituted oxadiazole, thiadiazole and triazole peptoids which are useful as inhibitors of serine proteases.
BACKGROUND OF THE INVENTION
The serine proteases are a class of enzymes which includes elastase, chymotrypsin, cathepsin G, trypsin and thrombin.
SUMMARY OF THE INVENTION
The compounds of the present invention are antagonists of the VLA-4 integrin ("very late antigen-4"; CD49d/CD29; or .alpha..sub.4.beta..sub.1), the .alpha..sub.4.beta..sub.7 integrin (LPAM-1 and .alpha..sub.4.beta..sub.p), and/or the .alpha..sub.9.beta..sub.1 integrin, and
The invention relates to imidazolyl-substituted phenylacetic acid prolinamides, processes for their preparation and their use in medicaments, in particular as hypotensive and antiatherosclerotic agents.
It is known that renin, a proteolytic enzyme, eliminates the decapeptide angiotensin I from
FIELD OF THE INVENTION
The present invention relates to constrained cyano compounds and to their use as selective inhibitors of post-proline/alanine cleaving amino-dipeptidases. The invention further relates to methods of employing such inhibitors, alone or with another therapeutic agent, to treat
FIELD OF THE INVENTION
This invention relates to the field of atherosclerosis. In particular, this invention pertains to the identification of a class of peptides that are orally administrable and that ameliorate one or more symptoms of atherosclerosis.
BACKGROUND OF THE INVENTION
Cardiovascular